Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115790 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study in Participants With Advanced Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 5
- Study locations
NCT01115790: Completed Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer, sponsored by Eli Lilly and Company.
NCT01115790 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01115790, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Advanced Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1\[chk 1\]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type (Part B). Part C of the study will evaluate prexasertib in three different groups of participants; those with squamous cell cancer of the head and neck that has recurred or spread to other parts of the body, those with squamous non-small cell lung cancer that has recurred or spread, and those with squamous cell cancer of the anus that is not curable by existing therapy.
Conditions Studied
Interventions
- DRUG Prexasertib
Study Locations (5)
Tennessee
- Sarah Cannon Research Institute SCRI - Nashville
- Tennessee Oncology PLLC - Nashville
Florida
- Florida Cancer Specialists - Sarasota
Oklahoma
- Peggy and Charles Stephenson Oklahoma Cancer Center - Oklahoma City
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-02 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
What the finished NCT01115790 record still lists
NCT01115790 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (54% lower).
The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.
NCT01115790 lists 5 locations in 4 states (Tennessee, Florida, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT01115790 about?
NCT01115790 is a clinical study titled "A Phase 1 Study in Participants With Advanced Cancer". The primary purpose of Parts A and B of this study is to evaluate the safety and toxicity of prexasertib (an inhibitor of checkpoint kinase 1\[chk 1\]) in participants with advanced or metastatic cancer (Part A), or squamous cell cancer of the head and neck or squamous cell cancer of any tumor type ...
What is the current status of trial NCT01115790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2010-02. Estimated completion is 2016-01.
What conditions does trial NCT01115790 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Advanced Cancer, Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck.
What interventions are being tested in trial NCT01115790?
The interventions under investigation include: Prexasertib (DRUG).
Who is sponsoring clinical trial NCT01115790?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115790 being conducted?
This trial has 5 study locations across Florida, Oklahoma, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01115790's enrollment target sits among peer trials
150 58th of 130 higher than 73 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia